Concepedia

Publication | Closed Access

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

DOI

71

Citations

21

References

2015

Year

Shuta Ikeda, Y. Takano, Osamu Cynshi, Reiko Tanaka, Andreas D. Christ, Viktor Boerlin, Ulrich Beyer, A. Beck, Cornelia Ciorciaro, Markus Meyer,
Diabetes Obesity and Metabolism

Abstract

A once-daily dose of tofogliflozin for 12 weeks was an effective, safe and well-tolerated treatment for T2DM.

References

YearCitations

Page 1